Literature DB >> 18000617

Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice.

Bruce S Sachais1, Tiffany Turrentine, Jennine M Dawicki McKenna, Ann H Rux, Daniel Rader, M Anna Kowalska.   

Abstract

Activated platelets, which release platelet factor 4 (PF4) are present in patients with atherosclerosis. To date, no direct in-vivo evidence exists for the involvement of PF4 in atherogenesis. In the current study, we tested the hypothesis that PF4 is atherogenic, and that genetic elimination of PF4 would protect mice from atherosclerosis. We have bred PF4(-/-) mice onto two athero-susceptible backgrounds, WT-C57Bl/6(WT) and apoE(-/-) to examine the importance of PF4 in atherogenesis. In order to induce atherosclerosis, WT and PF4(-/-) mice were fed an atherogenic diet for 30 weeks, while apoE(-/-) and apoE(-/-) PF4(-/-) mice were fed a high-fat Western-style diet for 10 weeks. Examination of lesions in the aortic roots of atherogenic diet fed mice demonstrated reduced atherosclerosis in PF4(-/-) (20% compared to WT). Examination of apoE(-/-) mice demonstrated similar changes, with apoE(-/-) PF4(-/-) mice demonstrating 37% of the aortic atherosclerotic burden compared to apoE(-/-) mice. Although we found similar levels of total and non-HDL cholesterol in WT and PF4(-/-) mice, HDL-cholesterol levels were increased in PF4(-/-) on both backgrounds. These data demonstrate, for the first time, that the platelet specific chemokine PF4 promotes atherosclerotic lesion development in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000617

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  58 in total

Review 1.  Platelets as initiators and mediators of inflammation at the vessel wall.

Authors:  Guanfang Shi; Craig N Morrell
Journal:  Thromb Res       Date:  2010-11-20       Impact factor: 3.944

Review 2.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE-/- mice.

Authors:  J R Hamilton; I Cornelissen; J K Mountford; S R Coughlin
Journal:  Atherosclerosis       Date:  2009-01-23       Impact factor: 5.162

4.  Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice.

Authors:  Sanjay Srivastava; Srinivas D Sithu; Elena Vladykovskaya; Petra Haberzettl; David J Hoetker; Maqsood A Siddiqui; Daniel J Conklin; Stanley E D'Souza; Aruni Bhatnagar
Journal:  Atherosclerosis       Date:  2011-03-02       Impact factor: 5.162

5.  Exposure to acrolein by inhalation causes platelet activation.

Authors:  Srinivas D Sithu; Sanjay Srivastava; Maqsood A Siddiqui; Elena Vladykovskaya; Daniel W Riggs; Daniel J Conklin; Petra Haberzettl; Timothy E O'Toole; Aruni Bhatnagar; Stanley E D'Souza
Journal:  Toxicol Appl Pharmacol       Date:  2010-08-03       Impact factor: 4.219

Review 6.  Monocyte and macrophage dynamics during atherogenesis.

Authors:  Klaus Ley; Yury I Miller; Catherine C Hedrick
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07       Impact factor: 8.311

Review 7.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

8.  Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury.

Authors:  Khalil Bdeir; Kandace Gollomp; Marta Stasiak; Junjie Mei; Izabela Papiewska-Pajak; Guohua Zhao; G Scott Worthen; Douglas B Cines; Mortimer Poncz; M Anna Kowalska
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

9.  Platelet factor 4 regulation of monocyte KLF4 in experimental cerebral malaria.

Authors:  Kalyan Srivastava; David J Field; Angela Aggrey; Munekazu Yamakuchi; Craig N Morrell
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

10.  Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention.

Authors:  Mark Slevin; Jerzy Krupinski; Lina Badimon
Journal:  J Angiogenes Res       Date:  2009-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.